Histostem Participates In Clinical Trials Demonstrating The Effective Use Of Its Proprietary Stem Cells In The Treatment Of Cirrhosis Of The Liver
AmStem Corporation (OTCBB: SCII) announced that Histostem Ltd. of South Korea (”Histostem”), has participated in a successful preclinical study of the use of its proprietary Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells (HMSCs) in the treatment of cirrhosis of the liver…
[Read the full article here]Related News:
Histostem Participates in Successful Stem Cell Treatment for Acute Spinal Cord Injury in Dogs
Stem Cell Therapy International to merge with Histostem Korea
Stem Cell Therapy International, Inc. Closes Merger With Histostem Ltd …